TY - JOUR
T1 - Cyclosporine for treating rheumatoid arthritis
AU - Wells, George A.
AU - Haguenauer, Didier
AU - Shea, Beverley
AU - Suarez-Almazor, Maria E.
AU - Welch, Vivian
AU - Tugwell, Peter
AU - Peterson, Joan
N1 - Funding Information:
The authors would like to thank the Cochrane Musculoskeletal Group for the valuable review of this document. Many thanks to Dr. Ann Cranney for editorial review of this manuscript.
Publisher Copyright:
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 1998/4/27
Y1 - 1998/4/27
N2 - Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by an activation of T lymphocyte and an increase in interleukine turnover. In RA, cyclosporine is known to be efficient as a Disease Modifying Anti-Rheumatic Agent (DMARD), especially when other treatments such as injectable gold, D-penicillamine or anti-malarials were not efficacious. Objectives: To estimate the short-term (up to one year) effects of cyclosporine for rheumatoid arthritis. Search methods: We searched the Cochrane Musculoskeletal Group trials register, and MEDLINE, up to 1997, using the search strategy developed by the Cochrane Collaboration (Dickersin 1994). The search was complemented with bibliography searching of the reference list of the trials retrieved from the electronic search. Key experts in the area were contacted for further published and unpublished articles. Selection criteria: All randomized clinical trials (RCTs) and controlled clinical trials (CCTs) comparing cyclosporine against placebo in patients with rheumatoid arthritis. Data collection and analysis: Two reviewers determined the trials to be included based on inclusion and exclusion criteria (GW, MSA). Data were independently abstracted by two reviewers (DH, GW),and checked by a third reviewer (BS) using a pre-developed form for the rheumatoid arthritis sub-group of the Cochrane Musculoskeletal Group. Methodological quality of the RCTs and CCTs was assessed by two reviewers (BS, DH). Rheumatoid arthritis outcome measures were extracted from the publications for change from baseline endpoints. Sufficient data were obtained to include in the pooled analysis the number of swollen joints, physician global assessment, patient global assessment and erythrocyte sedimentation rate (ESR). Main results: Three trials and 318 patients were included. A statistically significant decrease in the number of tender and swollen joints was observed for cyclosporine when compared to placebo. The standardized mean difference (SMD) for the change in the number of swollen joints was -0.969. Significant improvements in pain and the functional index were also found for cyclosporine. More side effects occurred in the cyclosporine group compared to placebo. Authors' conclusions: Cyclosporine has an important clinical benefit in the short-term (up to one year) treatment of patients with progressive rheumatoid arthritis.
AB - Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by an activation of T lymphocyte and an increase in interleukine turnover. In RA, cyclosporine is known to be efficient as a Disease Modifying Anti-Rheumatic Agent (DMARD), especially when other treatments such as injectable gold, D-penicillamine or anti-malarials were not efficacious. Objectives: To estimate the short-term (up to one year) effects of cyclosporine for rheumatoid arthritis. Search methods: We searched the Cochrane Musculoskeletal Group trials register, and MEDLINE, up to 1997, using the search strategy developed by the Cochrane Collaboration (Dickersin 1994). The search was complemented with bibliography searching of the reference list of the trials retrieved from the electronic search. Key experts in the area were contacted for further published and unpublished articles. Selection criteria: All randomized clinical trials (RCTs) and controlled clinical trials (CCTs) comparing cyclosporine against placebo in patients with rheumatoid arthritis. Data collection and analysis: Two reviewers determined the trials to be included based on inclusion and exclusion criteria (GW, MSA). Data were independently abstracted by two reviewers (DH, GW),and checked by a third reviewer (BS) using a pre-developed form for the rheumatoid arthritis sub-group of the Cochrane Musculoskeletal Group. Methodological quality of the RCTs and CCTs was assessed by two reviewers (BS, DH). Rheumatoid arthritis outcome measures were extracted from the publications for change from baseline endpoints. Sufficient data were obtained to include in the pooled analysis the number of swollen joints, physician global assessment, patient global assessment and erythrocyte sedimentation rate (ESR). Main results: Three trials and 318 patients were included. A statistically significant decrease in the number of tender and swollen joints was observed for cyclosporine when compared to placebo. The standardized mean difference (SMD) for the change in the number of swollen joints was -0.969. Significant improvements in pain and the functional index were also found for cyclosporine. More side effects occurred in the cyclosporine group compared to placebo. Authors' conclusions: Cyclosporine has an important clinical benefit in the short-term (up to one year) treatment of patients with progressive rheumatoid arthritis.
UR - http://www.scopus.com/inward/record.url?scp=85019588677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019588677&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD001083
DO - 10.1002/14651858.CD001083
M3 - Article
C2 - 10796412
AN - SCOPUS:85019588677
SN - 1465-1858
VL - 2010
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 7
M1 - CD001083
ER -